Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

13.6K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
13.6K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

8.2K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
8.2K
Cancer Therapies02:49

Cancer Therapies

9.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Leukemia·2026
Same author

Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis.

Blood advances·2025
Same author

Distinct B/myeloid and T-lymphoblast populations at separate anatomic sites in mixed-phenotype acute leukemia with BCR::ABL1 fusion.

Journal of hematopathology·2025
Same author

Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma.

Blood cancer journal·2025
Same author

Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma.

Research square·2025

Related Experiment Video

Updated: Nov 25, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.5K

New agents and regimens for diffuse large B cell lymphoma.

Liang Wang1,2, Lin-Rong Li3, Ken H Young4

  • 1Department of Hematology, Beijing TongRen Hospital, Capital Medical University, Beijing, 100730, China. wangliangtrhos@126.com.

Journal of Hematology & Oncology
|December 15, 2020
PubMed
Summary

Standard R-CHOP therapy cures most diffuse large B cell lymphoma (DLBCL) patients, but relapsed/refractory cases require novel treatments. This review covers emerging DLBCL therapies and genetic classifications for personalized medicine.

Keywords:
ChemoresistanceChimeric antigen receptor T cellsDiffuse large B cell lymphomaGenetic classificationImmunotherapyNovel agents

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.6K

Related Experiment Videos

Last Updated: Nov 25, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

21.6K

Area of Science:

  • Oncology
  • Hematology
  • Immunotherapy

Background:

  • Diffuse large B cell lymphoma (DLBCL) is a common non-Hodgkin lymphoma.
  • The standard R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) cures approximately two-thirds of DLBCL patients.
  • A significant proportion of patients develop refractory or relapsed disease, necessitating alternative treatment strategies.

Purpose of the Study:

  • To review current and emerging treatment modalities for DLBCL.
  • To introduce novel genetic classification systems for DLBCL.
  • To guide the development of individualized treatment approaches for DLBCL patients.

Main Methods:

  • Literature review of up-to-date data on DLBCL treatments.
  • Analysis of novel genetic classification systems for DLBCL.
  • Synthesis of information on emerging therapies including CAR T-cells, bispecific antibodies, and targeted agents.

Main Results:

  • R-CHOP remains a standard but has limitations for refractory/relapsed DLBCL.
  • Numerous novel therapeutic strategies are under investigation, showing promise.
  • New genetic classifications may enable more precise patient stratification and treatment selection.

Conclusions:

  • Despite advances, refractory/relapsed DLBCL presents significant challenges.
  • Emerging therapies offer new hope for patients with resistant disease.
  • Individualized treatment guided by genetic profiling is the future direction for DLBCL management.